These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14977485)

  • 1. The prospects for neuroprotection in MS.
    Hohlfeld R
    Int MS J; 2003 Dec; 10(4):103-5. PubMed ID: 14977485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated neurodegeneration and neuroprotection in MS.
    Giuliani F; Yong VW
    Int MS J; 2003 Dec; 10(4):122-30. PubMed ID: 14977489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurodegeneration and neuroprotection in multiple sclerosis].
    Davydovskaia MV; Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
    Bansal R; Singh R
    Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R; Arnon R
    Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotection in the treatment of multiple sclerosis].
    Zipp F; Gold R
    Nervenarzt; 2011 Aug; 82(8):973-7. PubMed ID: 21761185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy.
    Hohlfeld R; Kappos L
    Int MS J; 2004 Sep; 11(2):61-3. PubMed ID: 15279736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for neuroprotection in multiple sclerosis.
    Yong VW
    Front Biosci; 2004 Jan; 9():864-72. PubMed ID: 14766415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing therapeutic options in multiple sclerosis with neuroprotective properties.
    Stroet A; Linker RA; Gold R
    J Neural Transm (Vienna); 2013 Sep; 120 Suppl 1():S49-53. PubMed ID: 23720188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T
    Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in multiple sclerosis: a therapeutic approach.
    Maghzi AH; Minagar A; Waubant E
    CNS Drugs; 2013 Oct; 27(10):799-815. PubMed ID: 23955320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
    Rottlaender A; Kuerten S
    Int J Mol Sci; 2015 Jul; 16(7):14850-65. PubMed ID: 26140377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
    Dhib-Jalbut S; Arnold DL; Cleveland DW; Fisher M; Friedlander RM; Mouradian MM; Przedborski S; Trapp BD; Wyss-Coray T; Yong VW
    J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodegeneration in multiple sclerosis: novel treatment strategies.
    Luessi F; Siffrin V; Zipp F
    Expert Rev Neurother; 2012 Sep; 12(9):1061-76; quiz 1077. PubMed ID: 23039386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MS as a gateway disease.
    Lublin FD
    J Neurol Sci; 2013 Oct; 333(1-2):73-5. PubMed ID: 23578792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia.
    Inglese M; Petracca M
    Schizophr Res; 2015 Jan; 161(1):94-101. PubMed ID: 24893901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroprotection therapy of multiple sclerosis with high doses of ethylmethylhydroxypyridine succinate].
    Prakhova LN; Ilves AG; Savintceva ZI; Mineev KK; Nikiforova IG; Rubanik KS; Kataeva GV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):73-78. PubMed ID: 28139615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.